国产熊去氧胆酸治疗原发性胆汁性肝硬化患者的随访

高峰; 张福奎; 贾继东

国产熊去氧胆酸治疗原发性胆汁性肝硬化患者的随访

详细信息

中图分类号: R575.22
计量
- 文章访问数: 2412
- HTML全文浏览量: 13
- PDF下载量: 949
- 被引次数: 0
出版历程
- 出版日期: 2008-04-20

Liver function changes of ursodeoxycholic acid made in china for patients with primary biliary cirrhosis.

摘要

摘要: 目的观察国产熊去氧胆酸对原发性胆汁性肝硬化患者肝功生化指标的影响。方法选择北京友谊医院经肝穿活检病理学或AMA-M2阳性而确诊的原发性胆汁性肝硬化患者,应用国产熊去氧胆酸（13-15）mg/kg day,分三次口服,定期（每隔3个月）复查肝功。结果从用药第三个月起,γ-GT、ALP、ALT、AST水平开始明显下降（P<0.05）。结论国产熊去氧胆酸可以改善原发性胆汁性肝硬化患者胆汁淤积相关指标（GGT、ALP）,降低转氨酶（ALT、AST）水平。
- 熊去氧胆酸 /
- 原发性胆汁性肝硬化 /
- 治疗
Abstract: Objective To observe the liver function changes of ursoderoxycholic acid made in China for patients with primary biliary cirrhosis.Methods Choose patients with primary biliary cirrhosis diagnosed by liver biopsy or AMAM2 positive, treated by ursodeoxycholic acids mades in China, 13-15mg·kg-1·day-1 oral administration.Check the liver function every three months.Results Serum concentration of alkaline phosphatase, γ-glutamylaminotranspeptidase, alanine and aspartate aminotransferases fall markedly since the third month from the use of UDCA made in China.Conclusion UDCA treatment is associated with a marked improvement in serum biochemical markers of cholestasis.
- ursodeoxycholic acid /
- primary biliary cirrhosis /
- treatment

HTML全文

参考文献(23)

[1]Heathcote E J.Management of primary biliary cirrhosis.The Ameri-can Association for the Study of liver disease practice guidelines[J].Hepatology, 2000, 31 (4) ∶1005-1013.

[2]Poupon RE, Bonnand AM, Chretien Y, et al.Ten-year survival inursodeoxycholic acid-treated patients with primary biliarycirrhosis[J].Hepatology, 1999, 29 (6) ∶1668-1671.

[3]Lazaridis KN, Gores GJ, Lindor KD.Ursodeoxycholic acid mecha-nisms of action and clinical use in hepatobiliary disorders[J].J Hep-atol, 2001, 35 (1) ∶134-146.

[4]Hagey LR, Crombie DL, Espinosa E, et al.Ursodeoxycholic acid inthe Ursidae:biliary bile acids of bears, pandas, and related carni-vores[J].J Lipid Res, 1993, 34 (11) ∶1911-17.

[5]Angulo P, Batts KP, Therneau TM, et al.Long term ursodeoxychol-ic acid delays histological progression in primary biliary cirrhosis[J].Hepatology, 1999, 29 (2) ∶644-7.

[6]Goulis J, Leandro G, Burroughs AK.Randomized controlled trials ofursodeoxycholic acid therapy for primary biliary cirrhosis:a meta-a-nalysis[J].Lancet, 1999, 354∶1053-60.

[7]Papatheodoridis GV, Adziyannis ES, Deutsch M, et al.Ursodeo-xycholic acid for primary biliary cirrhosis:final results of a 12-year, prospective, randomized, controlled trial[J].Am J Gastroenterol, 2002, 97 (8) ∶2063-2070.

[8]张福奎, 贾继东, 王宝恩, 等.45例原发性胆汁性肝硬化的临床特征[J].中华内科杂志, 2002, 41 (1) ∶163-167.

[9]陈国凤, 马威, 李莉, 等.47例原发性胆汁性肝硬化的临床分析[J].肝脏, 2003, 8 (1) ∶38-39.

[10]崔恩斌, 李征, 张忠兵.原发性胆汁性肝硬化21例临床分析[J].中国实用内科杂志, 2003, 23 (2) ∶116-117.

[11]Poupon R, Chretien Y, Poupon RE, et al.Is ursodeoxycholic acidan effect treatment for primary biliary cirrhosis?[J].Lancet, 1987, 1 (8537) ∶834-6.

[12]Batta AK, Arora R, Salen G, et al.Characterization of serum andurinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry:effect of UDCAtreatment[J].Journal of Lipid research, 1989, 30 (1) ∶1953-1962.

[13]Jazrawi RP, Caestecker JS, Goggin PM, et al.Kinetics of hepaticbile acid handling in cholestatic liver disease:elicit of ursodeoxychol-ic acid[J].Gastroenterology, 1994, 106 (1) ∶134-42.

[14]Paumgartner G, Beuers U.Ursodeoxycholic acid in cholestatic liverdisease:mechanisms of action and therapeutic use revisited[J].Hep-atology, 2002, 36 (3) ∶525-531.

[15]Faubion W, Guicciardi M, Miyoshi H, et al.Toxic bile salts in-duce rodent hepatocyte apoptosis via direct activation of Fas[J].JClin Invest, 1999, 103 (1) ∶137-145.

[16]Benz C, Angermuller S, ToxU, et al.Effect of tauroursodeoxychol-ic acid on bile-acid-induced apoptosis and cytolysis in rat hepato-cytes[J].J Hepatol, 1998, 28 (1) ∶99-106.

[17]Qiao L, Yacoub A, Studer E, et al.Inhibition of the MAPK andPI3K pathways enhances UCDA-induced apoptosis in primary ro-dent hepatocytes[J].Hepatology, 2002, 35 (3) ∶779-789.

[18]Rodrigues CM, Steer CJ.The therapeutic effects of ursodeoxych-olic acid as an anti-apoptotic agent[J].Expert Opin InvestigDrugs.2001, 10 (7) ∶1243-53.

[19]Setchell KDR, Rodrigues CMP, Clerici C, et al.Bile acid concen-trations in human and rat liver tissue and in hepatocyte nuclei[J].Gastroenterology, 1997, 112 (2) ∶226-35.

[20]Guldotana S, Zimmer G, Immhol M, et al.Molecular aspects ofmembrance stabilization by ursodeoxycholate[J].Gastroenterology, 1993, 104 (6) ∶1736-44.

[21]Alpini G, Baiochchi L, Glaser S, et al.Ursodeoxycholate and taur-oursodeoxycholate inhibit cholangiocyte growth and secretion of BDLrats through activation of PKC alpha[J].Hepatology, 2002, 35 (5) ∶1041-1052.

[22]Christophe C, Fabrice C, Raoul P, et al.Primary biliary cirrhosis:Incidence and predictive factors of cirrhosis development in Ursodiol-treated patients[J].Gastroenterology, 2002, 122 (2) ∶652-658.

[23]Poupon RE, Lindor KD, Pares A, et al.Combined analysis of theeffect of treatment with ursodeoxycholic acid on histologic progressionin primary biliary cirrhosis[J].J Hepatol, 2003, 39 (1) ∶12-16.

施引文献

资源附件(0)

访问统计